Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer (NSCLC) in China. The purpose of this study was to determine whether using camrelizumab in the first-line setting is cost-...

Full description

Bibliographic Details
Main Authors: Liu Qiao, Zhen Zhou, Xiaohui Zeng, Chongqing Tan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
nonsquamous non–small-cell lung cancer
camrelizumab
pembrolizumab
pemetrexed
China
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.728440/full

Similar Items

Similar Items